Health Insurance Review Service Announces Results of Pharmaceutical Reimbursement Evaluation Committee’s Second Discussion
On the 1st, the Health Insurance Review and Assessment Service released the results of the second discussion of the Pharmaceutical Reimbursement Evaluation Committee. [메디칼업저버 이주민 기자] Enhertu (trastuzumab deruxtecan) and Ilaris injection (canakinumab, genetically recombinant) passed the Pharmaceutical Reimbursement Evaluation Committee review and were recognized as appropriate for reimbursement. However, Ilaris injection was only approved […]
The Delayed Access to IL-17A Inhibitors: The Frustrations and Urgent Needs in Ankylosing Spondylitis Treatment
Seungjae Hong, Professor of Rheumatology at Kyung Hee University Hospital and Director of Insurance at the Korean Society of Rheumatology, emphasized the proven therapeutic efficacy and safety of Interleukin-17A (IL-17A) inhibitors in various studies. He stressed the importance of early application of these inhibitors to provide immediate benefits to patients and alleviate their pain. He […]
Reblozil and Coselugo Denied Reimbursement by Pharmaceutical Review Board
New Findings from the Pharmaceutical Reimbursement Evaluation Committee According to recent findings from the 8th review of the Pharmaceutical Reimbursement Evaluation Committee, several groundbreaking treatments have been recognized for their benefits. However, there are a few disappointments in terms of reimbursement. Positive Reimbursement Decisions One notable success is GlaxoSmithKline’s Gempery, a treatment for endometrial cancer. […]
Endometrial cancer drug ‘Jempery’ passed the first reimbursement hurdle
[메디칼업저버 박서영 기자] Zempery (ingredient: dolumumab), which was consistently requested for reimbursement at the treatment site, has passed the cancer screening barrier. As a result, attention is focused on whether the treatment paradigm for endometrial cancer can be established from chemotherapy to immunotherapy. The Health Insurance Review and Assessment Service on the 14th published the […]
Acknowledged for the adequacy of the reimbursement for the treatment of SMA Evrysdi Dry Syrup
[메디칼업저버 박서영 기자] Evrysdi dry syrup (ingredient: lead syrup), a treatment for spinal muscular atrophy (SMA), has been recognized for its scope. On the 1st, the Health Insurance Review and Assessment Service revealed the results of the 2023 Pharmaceutical Reimbursement Evaluation Committee’s 6th review. Two drugs have been approved for reimbursement, Eachs D Roche Korea […]
